Osteopore

Osteopore FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Osteopore (OSX.AX) as of Oct 28, 2026 is 68.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 92.55 % — a change of -25.46% (lower).

FCF Conversion

68.98 %

YoY

-25.46%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Osteopore is 2025 68.98 % . FCF Conversion Rate (FCF/EBITDA) of Osteopore was 2024 92.55 % . It decreases by -25.46% lower compared to the previous year.

The Osteopore FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
46.04 AUD
Jan 1, 2019
76.69 AUD
Jan 1, 2020
109.91 AUD
Jan 1, 2021
110.48 AUD
Jan 1, 2022
96.34 AUD
Jan 1, 2023
76.86 AUD
Jan 1, 2024
92.55 AUD
Jan 1, 2025
68.98 AUD
The Osteopore FCF Conversion history
YEARFCF ConversionYoY
68.98 %-25.46%
92.55 %+20.41%
76.86 %-20.22%
96.34 %-12.80%
110.48 %+0.51%
109.91 %+43.31%
76.69 %+66.60%
46.04 %+441.08%
8.51 %-67.91%
26.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Osteopore Stock analysis

What does Osteopore do? Osteopore Ltd. develops and markets bioresorbable polymer implants for neurosurgical, orthopaedic, and maxillofacial surgeries. The company commercializes bespoke products engineered to facilitate bone healing, utilizing patented technology that fabricates micro-structured scaffolds through 3D printing and bioresorbable materials. Key products include Osteoplug in plug and strip configurations for craniotomy gap filling, Osteomesh, and Osteoplug-C for craniofacial applications. These solutions support bone tissue integration from the skull to the bone flap, targeting procedures such as cranioplasty, craniosynostosis, and guided bone regeneration. The company serves medical professionals and healthcare facilities requiring advanced bone regeneration solutions. Its products are designed for specific surgical applications including craniotomy, orbital floor reconstruction, socket preservation, and minimally invasive skull base surgery. Osteopore Ltd. focuses on delivering patient-specific implants (PSI) for cranial and mandibular procedures, alongside solutions for burr hole restoration with shunt drainage systems. These offerings cater to specialized surgical segments demanding precision and biocompatibility. Osteopore Ltd.'s revenue streams derive from the sale of its proprietary implant systems to hospitals and surgical centers. The company’s technology enables the production of custom implants that address complex bone healing needs, particularly in neurosurgery, orthopaedics, and maxillofacial procedures. By providing tailored solutions for cranioplasty, craniosynostosis, and guided bone regeneration, the company meets the demands of healthcare providers seeking effective bone regeneration technologies. Osteopore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Osteopore stock

FCF Conversion Rate (FCF/EBITDA) of Osteopore is 68.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Osteopore changed from 92.55 % to 68.98 %, representing a -25.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Osteopore since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Osteopore with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Osteopore

All Key Metrics — Osteopore